Neurotech International (ASX:NTI) opened an authorized prescriber program for its therapy candidate NTI164, across a range of neurodevelopmental conditions for paediatric patients in Australia, according to a Tuesday Australian bourse filing.

The program aims to generate real-world clinical data to complement the ongoing and planned clinical and registration trials, and the data will provide further evidence of safety and efficacy across a broader patient population and strengthen regulatory submissions, advocacy efforts, and partnering discussions.

The launch of the program follows recent changes to the National Disability Insurance Scheme, which will see children with mild to moderate autism spectrum disorder diverted off the NDIS and into a newly established program by mid-2027.

The company's shares rose 6% in recent Tuesday trade.